Immune thrombotic thrombocytopenic purpura (TTP) can be treated safely and effectively with caplacizumab.
Cases of immune thrombotic thrombocytopenic purpura (iTTP) that are refractory to plasma exchange, treated through readministration, and do not include previous plasma exchange treatment could be treated with caplacizumab safely and effectively, according to a study published in Frontiers in Medicine. No major adverse events were reported when patients took the medicine.
A severe deficiency of ADAMTS13 is used to indicate a diagnosis of iTTP. Treatment usually involves plasma exchange and immunosuppression to replenish ADAMTS13 in patients with TTP. Caplacizumab has also been approved as a treatment for iTTP following trials that found it can speed up platelet recovery and reduce recurrence. The present study aimed to test the safety and efficacy of caplacizumab in a real-world setting using a multicenter design.
Red blood cells circulating in the blood vessels | Image credit: Design Cells - stock.adobe.com
Data from adults 18 years and older with iTTP diagnosed between 2011 and 2022 were collected. Clinical presentation and the measurement of ADAMTS13 in plasma was used to diagnose iTTP, and levels of ADAMTS13 were used to determine how long caplacizumab would be given until ADAMTS13 activity was raised to 10% or higher.
Eleven hematology departments in Greece and the United Kingdom were included in the study, and patient records were recorded retrospectively. The participating centers mostly treated patients with iTTP using steroids and daily plasma exchange. The control group, which consisted primarily of patients who were refractory or who had relapsed or patients who had severe presentation, received rituximab. Relapse was defined as deterioration after 30 days in remission.
Seventy patients were included in this study—47 patients in the control group and 23 in the caplacizumab group—and their median (IQR) age was 45 (19-85) years. All but 2 patients received plasma exchange, all patients received corticosteroids, and most also received rituximab. Patients in the caplacizumab group more frequently used rituximab as first-line treatment compared with the control group (68% vs 32%).
Patients were given caplacizumab a median 7 (1-43) days after diagnosis, for a median of 32 (6-47) doses. Sixty-fice percent of patients used caplacizumab for their first episode of iTTP. All but 4 patients intended to use caplacizumab as their first treatment, with the 4 only using the medication after being unresponsive to plasma exchange. Seventy percent of cases were given caplacizumab within 72 hours of their diagnosis, with 2 cases having iTTP occurring after COVID-19 infection. Plasma exchange sessions occurred a median of 12 (8-23) times in the caplacizumab group vs 14 (6-32) times in the control group.
All patients had early platelet normalization a median of 5 (3-7) days after administration of caplacizumab, and ADAMTS13 levels became detectable (25%-52%) by the end of treatment in all patients receiving caplacizumab. The timing of caplacizumab initiation, whether within 72 hours of diagnosis or after, did not have a significant different in platelet recovery or plasma exchange duration. Two of the 23 patients who received caplacizumab relapsed within 13 and 18 months of their first dose compared with 29 of the 47 patients who were in the control group. After restarting caplacizumab, both patients had platelet count normalize within 10 and 4 days. Only 1 death occurred in the caplacizumab group compared with 4 in the control group.
Administration of caplacizumab did not lead to major bleeding events or a grade 3 complication. Twnety-one percent of patients who received caplacizumab reported minor bleeding events vs 15% of the control group.
The researchers concluded that caplacizumab was safe and effective in treating patients with iTTP. Rapid platelet recovery and low relapse rates were associated with caplacizumab, even as overall therapeutic plasma exchange duration did not differ.
Reference
Gavriilaki E, Nikolousis E, Koravou EE, et al. Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data. Front Med. Published online October 11, 2023. doi:10.3389/fmed.2023.1226114
Overdiagnosis of Adult ADHD Is Exacerbating the Stimulant Shortage
March 11th 2025The authors argue that the stimulant shortage is being perpetuated by the overdiagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults because executive functioning deficits are not included in diagnostic criteria.
Read More
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More